International Clinical Trial: A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 = 50%. (ROSETTA Lung-202)

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07361510) titled 'A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 = 50%. (ROSETTA Lung-202)' on Jan. 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Bristol-Myers Squibb

Condition: Non-Small Cell Lung Cancer (NSCLC)

Intervention: Drug: Pumitamig

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 9, 2026

Target Sample Size: 750

Countries...